Evidence map›Paper›PMID 42443181›Full record

ArticleNature communications2026

A ribozyme ligase that requires a 3' terminal phosphate on its RNA substrate.

Annyesha Biswas, Zoe Weiss, Jack W Szostak, Saurja DasGupta

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Annyesha BiswasDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN, USA.
Zoe WeissHarvard/Massachusetts Institute of Technology MD-PhD Program, Harvard Medical School, Boston, MA, USA.
Jack W SzostakHoward Hughes Medical Institute, The University of Chicago, Chicago, IL, USA. jwszostak@uchicago.edu.ORCID 0000-0003-4131-1203
Saurja DasGuptaDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN, USA. sdasgupta@nd.edu.ORCID 0000-0002-9064-9131

Funding

Medical Scientist Training ProgramT32GM144273 · NIGMS · HARVARD MEDICAL SCHOOL · PI David Shumway Jones, Jacqueline A. Lees · 2022 to 2026
$14.7M
NIGMS NIH HHS T32 GM144273Simons Foundation 290363
6 · The paper itself

Abstract

Ribozymes likely played essential roles in catalyzing metabolic processes and facilitating genome replication in primordial RNA-based life. In vitro evolution has allowed us to expand the biochemical capabilities of RNA, especially new ribozyme chemistries. Here, we report the serendipitous discovery of ribozyme ligases that catalyze the attack of the 2'-hydroxyl group of an RNA substrate on its own 5'-triphosphate group, but only when the substrate possesses a 3'-phosphate vicinal to its nucleophilic 2'-hydroxyl group. The ligases' requirement for a 3'-phosphate group on its substrate resembles enzymatic mechanisms found in protein-based RNA repair pathways. We propose that ribozyme-catalyzed ligation of 3'-phosphorylated RNA could have provided pathways for RNA repair in primordial cells. We demonstrate that these ribozymes ligate specifically to 3'-phosphorylated RNA present in a heterogeneous mixture of cellular RNAs. We further show that these ribozymes can capture cleaved RNAs with 3'-phosphate and 2'-3'-cyclic phosphate termini, enabling us to selectively amplify the captured RNAs. These results demonstrate their potential utility as enrichment reagents for profiling RNA cleavage products in transcriptomics studies. Our findings not only report a new catalytic reactivity in RNA but also provide insights into ribozyme evolution, primordial RNA repair, and potential applications in RNA sequencing.

Indexed as

LigasesPhosphatesRNARNA, CatalyticRNA Ligase (ATP)PhosphorylationSubstrate SpecificityLigasesPhosphatesRNARNA, CatalyticRNA Ligase (ATP)

Identifiers

PMID42443181
PMCPMC13365474

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.